| Authors: |
Mitchell JM; Department of Neurology, University of California San Francisco, San Francisco, CA, USA. jennifer.mitchell@ucsf.edu.; Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA. jennifer.mitchell@ucsf.edu., Bogenschutz M; Department of Psychiatry, New York University Grossman School of Medicine, New York, NY, USA., Lilienstein A; Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, CA, USA., Harrison C; MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA., Kleiman S; Kleiman Consulting and Psychological Services, Sayreville, NJ, USA., Parker-Guilbert K; KPG Psychological Services LLC, Brunswick, ME, USA., Ot'alora G M; Aguazul-Bluewater Inc., Boulder, CO, USA.; MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA., Garas W; Aguazul-Bluewater Inc., Boulder, CO, USA., Paleos C; Nautilus Sanctuary, New York, NY, USA., Gorman I; Fluence, Woodstock, NY, USA., Nicholas C; Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Mithoefer M; MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA.; MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA.; Medical University of South Carolina, Charleston, SC, USA., Carlin S; MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA.; MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA., Poulter B; Aguazul-Bluewater Inc., Boulder, CO, USA.; MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA., Mithoefer A; MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA., Quevedo S; Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA.; San Francisco Insight and Integration Center, San Francisco, CA, USA., Wells G; San Francisco Insight and Integration Center, San Francisco, CA, USA., Klaire SS; British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada., van der Kolk B; Boston University School of Medicine, Boston, MA, USA., Tzarfaty K; MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA., Amiaz R; Chaim Sheba Medical Center, Tel HaShomer, Israel., Worthy R; Ray Worthy Psychiatry LLC, New Orleans, LA, USA., Shannon S; Wholeness Center, Fort Collins, CO, USA., Woolley JD; Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA., Marta C; New School Research LLC, North Hollywood, CA, USA., Gelfand Y; Zen Therapeutic Solutions, Mt Pleasant, SC, USA., Hapke E; University of Toronto, Toronto, Ontario, Canada., Amar S; Dr Simon Amar Inc., Montreal, Quebec, Canada., Wallach Y; Be'er Ya'akov Ness Ziona Mental Health Center, Be'er Ya'akov, Israel., Brown R; Fluence, Woodstock, NY, USA., Hamilton S; Stanford School of Medicine, Stanford, CA, USA., Wang JB; MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA., Coker A; Department of Neurology, University of California San Francisco, San Francisco, CA, USA.; MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA., Matthews R; MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA., de Boer A; MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA., Yazar-Klosinski B; Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, CA, USA., Emerson A; MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA., Doblin R; Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, CA, USA. |
